Evidence map›Paper›PMID 41111138›Full record

SynthesisCardiovascular and interventional radiology2026

Complication Rates and Effectiveness of Renal Angiomyolipoma Embolisation: A Systematic Review and Meta-analysis.

Michael Duffy, Avinash Deshwal, Ryan Donnelly, Abhinav Deshwal, Aaron Mau, Rohan Modi, Ethel Mc Manus, Matthew Mullins

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation.Journal of medical imaging and radiation oncology · 2026
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael DuffyTallaght University Hospital, Dublin, Ireland. Michaelduffy9595@gmail.com.ORCID http://orcid.org/0000-0001-5113-2212
Avinash DeshwalFiona Stanley Hospital, Perth, Australia.
Ryan DonnellySaint Vincent's University Hospital, Dublin, Ireland.
Abhinav DeshwalUniversity of Nottingham, Nottingham, UK.
Aaron MauFiona Stanley Hospital, Perth, Australia.
Rohan ModiSunshine Coast University Hospital, Birtinya, Australia.
Ethel Mc ManusFiona Stanley Hospital, Perth, Australia.
Matthew MullinsFiona Stanley Hospital, Perth, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the rates of success, complications, and re-interventions of selective arterial embolisation of renal angiomyolipomas. MATERIALS AND

methodsA systematic review and meta-analysis was conducted, including studies reporting outcomes of selective arterial embolisation for renal angiomyolipomas. Pooled estimates were calculated for technical success, radiological success, clinical success, tumour shrinkage, re-embolisation rates, surgical re-intervention, and complication rates. Heterogeneity was assessed using I

resultsThirteen studies comprising 478 patients and 542 AMLs were included. Technical success-successful delivery and occlusion of the embolic agent-was achieved in 86.2% of cases (95% CI 80-89.1%; I CONCLUSION AND CONTRIBUTION: Embolisation is a safe primary treatment option for renal angiomyolipomas with high technical and radiologic success, low major complications, and rates of surgical intervention. Embolic agent choice significantly impacted outcomes in this cohort.

Indexed as

AngiomyolipomaEmbolization, TherapeuticKidney NeoplasmsHumansTreatment OutcomeComplicationsEmbolisationRenal angiomyolipomaTechnical successTuberous sclerosisTumour shrinkage

Identifiers

PMID41111138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.